Voyager Therapeutics (VYGR) Resumen de Acciones
Voyager Therapeutics, Inc. es una empresa de biotecnología centrada en la genética humana para la cura de enfermedades neurológicas. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 2/6 |
| Crecimiento futuro | 1/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
VYGR Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Voyager Therapeutics, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$3.80 |
| Máximo en las últimas 52 semanas | US$5.55 |
| Mínimo de 52 semanas | US$2.65 |
| Beta | 1.26 |
| Cambio en 1 mes | -8.21% |
| Variación en 3 meses | 8.88% |
| Cambio de 1 año | 30.14% |
| Variación en 3 años | -68.46% |
| Variación en 5 años | -10.80% |
| Variación desde la OPV | -78.59% |
Noticias y actualizaciones recientes
Artículo de análisis • May 07
Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Actualización de narrativa • May 04
VYGR: Leadership Transition And Future P/E Stability Will Drive Upside
Analysts have maintained their $25.00 price target for Voyager Therapeutics, noting only minor adjustments to their model inputs, including a slightly different discount rate, revenue growth assumption, profit margin forecast, and future P/E multiple. What's in the News Chief Financial Officer Nathan Jorgensen, Ph.D. notified Voyager Therapeutics on April 15, 2026, that he will resign from his role and all other positions at the company, effective May 8, 2026, to pursue a new opportunity (Key Developments).Actualización de narrativa • Apr 19
VYGR: Future P/E Stability Will Drive Upside From Cash And Milestone Optionality
Analysts kept their price target for Voyager Therapeutics steady at $25.00, reflecting small tweaks to underlying assumptions, such as a slightly higher discount rate, modest adjustments to revenue growth and profit margin expectations, and a marginal shift in the very large future P/E input. Valuation Changes $Fair Value remained unchanged at $25.00.Recent updates
Artículo de análisis • May 07
Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Actualización de narrativa • May 04
VYGR: Leadership Transition And Future P/E Stability Will Drive Upside
Analysts have maintained their $25.00 price target for Voyager Therapeutics, noting only minor adjustments to their model inputs, including a slightly different discount rate, revenue growth assumption, profit margin forecast, and future P/E multiple. What's in the News Chief Financial Officer Nathan Jorgensen, Ph.D. notified Voyager Therapeutics on April 15, 2026, that he will resign from his role and all other positions at the company, effective May 8, 2026, to pursue a new opportunity (Key Developments).Actualización de narrativa • Apr 19
VYGR: Future P/E Stability Will Drive Upside From Cash And Milestone Optionality
Analysts kept their price target for Voyager Therapeutics steady at $25.00, reflecting small tweaks to underlying assumptions, such as a slightly higher discount rate, modest adjustments to revenue growth and profit margin expectations, and a marginal shift in the very large future P/E input. Valuation Changes $Fair Value remained unchanged at $25.00.Seeking Alpha • Apr 13
Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026
Summary Voyager Therapeutics maintains a "Strong Buy" rating as it approaches a pivotal 2026 catalyst with tau PET imaging data from its phase 1b study in Alzheimer's disease. Company's anti-tau monoclonal antibody VY7523 demonstrated an excellent safety and PK profile in phase 1 SAD, enabling advancement to phase 1b MAD in early AD patients. Company's robust cash position, projected to fund operations into 2028, is further supported by potential $2.4B in milestone payments and ongoing collaborations. Additional upside exists with VY1706 tau-silencing gene therapy and multiple partnered programs, though key risks hinge on upcoming clinical data and regulatory milestones. Read the full article on Seeking AlphaActualización de narrativa • Apr 03
VYGR: Future P/E Stability Will Support Upside From Cash And Milestone Optionality
Analysts maintained their Voyager Therapeutics price target at $25.00, citing only minor adjustments in assumptions such as discount rate, revenue growth, profit margin and future P/E that did not materially affect their overall valuation view. Valuation Changes Fair Value: Held steady at $25.00 per share, with no change in the analysts' central estimate.Actualización de narrativa • Mar 19
VYGR: Higher Future P/E Will Support Upside From Cash And Milestone Optionality
Analysts have kept their Voyager Therapeutics price target steady at $25.00, with updated assumptions reflecting a slightly lower discount rate, more measured revenue growth, a much slimmer profit margin, and a very large projected future P/E multiple. Together, these factors signal a more cautious outlook on profitability while holding the same headline valuation.Actualización de narrativa • Mar 04
VYGR: Higher Future P/E Will Support Upside From Cash And Milestone Optionality
Analysts have kept their $25.00 price target for Voyager Therapeutics unchanged, citing updated assumptions around discount rate, revenue growth, profit margin, and future P/E that offset each other overall. Valuation Changes Fair Value: $25.00 unchanged, with the updated inputs offsetting each other in the model.Actualización de narrativa • Feb 17
VYGR: Refined Assumptions Will Reinforce Upside From Cash And Milestone Optionality
Analysts kept their $25.00 price target for Voyager Therapeutics unchanged, noting only very small tweaks in the discount rate, revenue growth assumptions, profit margin, and future P/E that do not materially alter their view. Valuation Changes Fair Value: Kept steady at $25.00, with no change in the estimated intrinsic value per share.Actualización de narrativa • Feb 03
VYGR: Neuro Data Readouts Will Reframe Upside From Cash And Milestone Optionality
Narrative Update Analysts trimmed their price target on Voyager Therapeutics to US$25 from US$30, citing the latest cash position of US$229m, potential partner milestones of up to US$2.4b, and progress in NeuroShuttle non viral delivery programs as key inputs to their updated outlook. Analyst Commentary Bullish analysts see the latest price target move to US$25 as a reset that still implies upside from current levels, supported by what they view as a solid capital position and a growing partnered pipeline.Actualización de narrativa • Jan 20
VYGR: Cash Strength And Milestone Upside Will Drive Neuro Data Repricing
Narrative Update on Voyager Therapeutics Analysts have trimmed their price target on Voyager Therapeutics to US$25 from US$30, citing strong Q3 cash of US$229m, eligibility for up to US$2.4b in partner milestones, and upcoming NeuroShuttle data as key factors shaping their outlook. Analyst Commentary Bullish analysts are adjusting their views while still highlighting what they see as solid execution and a meaningful cash position at Voyager Therapeutics.Actualización de narrativa • Jan 06
VYGR: Cash And Milestone Optionality Will Support Upcoming Neuro Data Repricing
Analysts have trimmed their price target on Voyager Therapeutics to US$25 from US$30, citing updated assumptions around future P/E multiples, while also highlighting the company’s Q3 cash position of US$229m, potential partner milestones of up to US$2.4b, and upcoming NeuroShuttle data as key drivers for the outlook. Analyst Commentary Bullish analysts continue to see a constructive setup for Voyager Therapeutics, even with the reduced price target, pointing to cash resources, milestone potential, and the NeuroShuttle platform as the core pieces of the story.Actualización de narrativa • Dec 15
VYGR: Cash Runway And Milestone Potential Will Drive Upside Ahead
Analysts have reduced their price target on Voyager Therapeutics by $5 to $25 per share, reflecting a modestly higher discount rate. They continue to highlight robust cash runway, significant milestone potential, and advancing NeuroShuttle data as key long term value drivers.Artículo de análisis • Nov 15
Benign Growth For Voyager Therapeutics, Inc. (NASDAQ:VYGR) Underpins Stock's 26% Plummet
Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) shares have retraced a considerable 26% in the last month, reversing a fair...Artículo de análisis • Nov 14
Earnings Update: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) just released its latest quarterly results and things are looking bullish...Artículo de análisis • Sep 25
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Held Back By Insufficient Growth Even After Shares Climb 27%
Despite an already strong run, Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) shares have been powering on, with a gain of...Artículo de análisis • May 27
It's Unlikely That The CEO Of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Will See A Huge Pay Rise This Year
Key Insights Voyager Therapeutics' Annual General Meeting to take place on 3rd of June Salary of US$652.1k is part of...Artículo de análisis • Feb 25
Positive Sentiment Still Eludes Voyager Therapeutics, Inc. (NASDAQ:VYGR) Following 27% Share Price Slump
Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) shareholders that were waiting for something to happen have been dealt a...Seeking Alpha • Jan 30
Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance
Summary Voyager Therapeutics, Inc.'s TRACER platform shows strong preclinical results for BBB-crossing gene therapies, securing multi-billion dollar deals with Novartis and Neurocrine, but lacks clinical trial data. VY7523, a monoclonal antibody for early Alzheimer's treatment, is expected to yield Phase I results by mid-2025, with potential undervaluation of VYGR shares. The competitive landscape includes Denali, Roche, and AbbVie, with varying BBB-crossing strategies, highlighting the speculative nature of investing in early-stage neurological therapies. I maintain a “Strong Buy” rating on VYGR shares for long-term, high-risk tolerant investors, emphasizing the speculative but promising potential of Voyager's TRACER platform and upcoming clinical trials. Read the full article on Seeking Alpha
Nueva narrativa • Jan 26
Developing Tau-Targeting Therapies Will Open Doors But May Encounter Setbacks
Strong partnerships and collaborations are expected to enhance revenue and earnings through milestone payments and shared R&D efforts.Seeking Alpha • Nov 18
Voyager Therapeutics' Tracer Platform Targets CNS Market: Here's Why I'm Neutral
Summary Voyager Therapeutics leverages its TRACER platform for targeted gene therapies, focusing on challenging CNS diseases like Alzheimer’s and ALS. Its pipeline includes a promising Phase 1 anti-tau Alzheimer’s therapy, VY7523, with data expected in 2025, but commercialization remains years away. Current valuation metrics indicate a balanced position, trading close to book value, suggesting potential but limited near-term catalysts. Key risks include reliance on collaboration revenues and the inherent difficulty of treating CNS disorders, warranting cautious optimism and a focus on future clinical trial updates. Despite promising technology and partnerships, VYGR faces long development timelines and challenging diseases, justifying a neutral "Hold" rating but worth watchlisting for 2025 R&D progress. Read the full article on Seeking AlphaArtículo de análisis • Oct 17
Improved Revenues Required Before Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock's 27% Jump Looks Justified
Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) shareholders are no doubt pleased to see that the share price has bounced...Seeking Alpha • Aug 26
Voyager Therapeutics: CNS Player In Early Stages Of A Turnaround
Summary Shares are trading at relative lows (down 20% YTD), but have gained +130% over the past 3 years. Collaborations with big name partners like Novartis and Neurocrine have validated Voyager's TRACER AAV capsid platform. Enabling delivery across the blood brain barrier could be extended to additional modalities outside of gene therapy. The company is still at the "science project" phase of development, lacking a clear path to market, although I appreciate management's focus on indications where surrogate endpoints have gained acceptance. I remain on the sidelines and may revisit in the late 2025 to early 2026 timeframe when the pipeline has made more progress. Read the full article on Seeking AlphaArtículo de análisis • Aug 09
Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) just released its second-quarter report and things are looking bullish. The...Artículo de análisis • Aug 08
Lacklustre Performance Is Driving Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Low P/S
With a price-to-sales (or "P/S") ratio of 2.7x Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) may be sending very bullish...Seeking Alpha • Jun 05
Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis
Summary Voyager Therapeutics, Inc. is a biotech company focused on developing gene-based therapies for neurological conditions. The company has made progress in its pipeline, including the start of the Phase 1 clinical trial for VY-TAU01, its Alzheimer's disease candidate. Voyager's strong revenue-driver partnerships and financial stability make it a "Strong Buy" for long-term investors. Read the full article on Seeking AlphaArtículo de análisis • Mar 15
There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise
Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) shares have had a really impressive month, gaining 28% after a shaky period...Seeking Alpha • Mar 08
Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier
Summary Voyager Therapeutics, a drug delivery specialist focused on AAV vectors for gene therapies, has faced many challenges, including partners walking away from deals, disappointing data, and management changes. The company has recently gained momentum through new partnerships and drug programs, attracting more than $8 billion in potential development and commercial milestone payments from three major pharma partners. Voyager's unique TRACER Capsid discovery platform and focus on gene therapy delivery make it an intriguing investment opportunity in the biotech industry. Investors will need to be patient with this company as it targets hard-to-treat CNS disease such as Alzheimer's and Parkinson's, but it's at the forefront of a promising field and I believe its best days are ahead of it. Read the full article on Seeking AlphaArtículo de análisis • Mar 04
What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates
Today is shaping up negative for Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) shareholders, with the analysts delivering...Artículo de análisis • Jan 04
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement
The Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) share price has done very well over the last month, posting an excellent...Rentabilidad de los accionistas
| VYGR | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 0.9% | 1.2% | 1.0% |
| 1Y | 30.1% | 34.9% | 28.7% |
Rentabilidad vs. Industria: Los resultados de VYGR fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 34.9% el año pasado.
Rentabilidad vs. Mercado: VYGR superó al mercado US, que obtuvo un rendimiento del 28.7% el año pasado.
Volatilidad de los precios
| VYGR volatility | |
|---|---|
| VYGR Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: VYGR no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de VYGR (10%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2013 | 141 | Al Sandrock | www.voyagertherapeutics.com |
Voyager Therapeutics, Inc. es una empresa de biotecnología centrada en la genética humana para la cura de enfermedades neurológicas. Su cartera de productos incluye VY1706, una terapia génica de silenciamiento de tau, y VY7523, un programa de anticuerpos antitau para el tratamiento de la enfermedad de Alzheimer. La empresa también ofrece un programa de investigación para el tratamiento de la enfermedad de Huntington.
Resumen de fundamentos de Voyager Therapeutics, Inc.
| Estadísticas fundamentales de VYGR | |
|---|---|
| Capitalización bursátil | US$222.35m |
| Beneficios(TTM) | -US$116.64m |
| Ingresos (TTM) | US$36.49m |
6.3x
Ratio precio-ventas (PS)-2.0x
Ratio precio-beneficio (PE)¿Está VYGR sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de VYGR | |
|---|---|
| Ingresos | US$36.49m |
| Coste de los ingresos | US$125.35m |
| Beneficio bruto | -US$88.86m |
| Otros gastos | US$27.78m |
| Beneficios | -US$116.64m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.93 |
| Margen bruto | -243.48% |
| Margen de beneficio neto | -319.61% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado VYGR a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/22 04:45 |
| Precio de las acciones al final del día | 2026/05/22 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Voyager Therapeutics, Inc. está cubierta por 25 analistas. 11 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Brian Skorney | Baird |
| Jack Allen | Baird |
| Aydin Huseynov | Benchmark Company |